Osiris Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Osiris Therapeutics, Inc.
Already owner of about 60% of the troubled antibiotic firm, Innoviva agrees to pay $2.20 per share for all outstanding stock in Entasis. Roche, KaliVir partner on oncolytic virus therapies.
The company is pushing ahead into Phase III development with the lower dose of an oral drug for ulcerative colitis, even though a Phase II study missed the primary endpoint.
Rising Leader Jing Lim is part of the team getting 3D implant and bone regenerating innovator Osteopore better known outside its founding base in Singapore. The company stands on the cusp of accelerated growth on the back of an expanding portfolio and its best practice approach to business building.
The third annual listing of In Vivo’s ‘Rising Leaders’ includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.
- Implantable Devices
- Gene Therapy, Cell Therapy
- Large Molecule